Αποτελέσματα Αναζήτησης
22 Μαΐ 2020 · This review summarizes morbidity and mortality outcomes in systemic sclerosis-related interstitial lung disease patients from high-quality observational and interventional studies over the last 50 years.
- Figure 1
Contemporary studies of systemic sclerosis consistently...
- Clinical and Genetic Factors Predictive of Mortality in Early Systemic Sclerosis
A limited number of variables collected at presentation,...
- Figure 1
9 Ιαν 2023 · The five-year survival rate (that is, patients who are still alive 5 years following diagnosis) among patients with diffuse cutaneous systemic sclerosis is about 84%. Five-year survival among patients with limited skin (cutaneous) systemic sclerosis is high — over 90%.
20 Ιαν 2021 · Review. Epidemiology. The incidence of SSc has been reported only in several European countries as well as the United States (US) and Canada. It is estimated to range between 0.6 and 2.3 per 100,000 individuals in Europe. Notably, in the US and Canada, the reported incidence is slightly higher, ranging between 1.4 and 5.6 per 100,000 individuals.
15 Ιαν 2024 · People who have interstitial lung disease along with systemic sclerosis are much more likely to die from disease complications than people who do not have lung disease. Around 80% to 90% are alive five years after being diagnosed with interstitial lung disease from systemic sclerosis.
Summary. Scleroderma is a multisystem disease characterized by a severe inflammatory process and exuberant fibrosis. Lung involvement is a frequent complication and a leading cause of morbidity and mortality in this syndrome.
15 Ιουν 2024 · When scleroderma affects the heart or lungs, it can cause shortness of breath, decreased exercise tolerance and dizziness. Scleroderma can cause scarring in the lung tissues that may result in increasing shortness of breath over time.
Lung transplantation can be lifesaving in patients with SSc end-stage lung disease. Although there is a perception amongst some physicians that patients with scleroderma will have poor post-transplant outcomes due to concomitant gastro-oesophageal disease, renal disease or skin fibrosis, 2- and 5-yr outcomes are similar to patients transplanted ...
